ReviewFrontiers in medicine2022
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Establishing C-X-C motif chemokine receptor 4 as a novel imaging target in giant cell arteritis.Arthritis research & therapy · 2026Trial
- Challenges and Future Trends in Large Vessel Vasculitis.Circulation · 2026Review
- Beyond clinical criteria: emerging biomarkers and advanced imaging in the diagnosis, monitoring and treatment of vasculitides.Frontiers in medicine · 2026Review
- PET and SPECT Imaging of Macrophages in the Tumor Stroma: An Update.Journal of clinical medicine · 2025Review
- Distinct landscapes of fibroblast subtypes in arteries of patients with giant cell arteritis.Rheumatology (Oxford, England) · 2025Article
- Innovations in Imaging:Current cardiology reports · 2024Review
- Article
- Multimodality imaging to assess diagnosis and evaluate complications of large vesselarteritis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2024Review
- Review
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- Advanced molecular imaging in large-vessel vasculitis: Adopting FDG-PET into a clinical workflow.Best practice & research. Clinical rheumatology · 2023Review
- Updates on the diagnosis and monitoring of giant cell arteritis.Frontiers in medicine · 2023Review
- 18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice.Frontiers in medicine · 2023Review
- Predictive Factors of Giant Cell Arteritis in Polymyalgia Rheumatica Patients.Journal of clinical medicine · 2022Review
- Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica.Frontiers in immunology · 2022Article
- Current developments in the diagnosis and treatment of giant cell arteritis.Frontiers in medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two interrelated inflammatory diseases affecting patients above 50 years of age. Patients with GCA suffer from granulomatous inflammation of medium- to large-sized arteries. This inflammation can lead to severe ischemic complications (e.g., irreversible vision loss and stroke) and aneurysm-related complications (such as aortic dissection). On the other hand, patients suffering from PMR present with proximal stiffness and pain due to inflammation of the shoulder and pelvic girdles. PMR is observed in 40-60% of patients with GCA, while up to 21% of patients suffering from PMR are also affected by GCA. Due to the risk of ischemic complications, GCA has to be promptly treated upon clinical suspicion. The treatment of both GCA and PMR still heavily relies on glucocorticoids (GCs), although novel targeted therapies are emerging. Imaging has a central position in the diagnosis of GCA and PMR. While [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.